Eli Lilly ROE 2006-2018 | LLY

Current and historical return on equity (ROE) values for Eli Lilly (LLY) over the last 10 years.
Eli Lilly Annual ROE - Return on Equity
2017 -1.75
2016 19.44
2015 16.51
2014 15.54
2013 26.56
2012 27.68
2011 32.12
2010 40.84
2009 45.45
2008 -30.75
2007 21.87
2006 24.25
2005 18.55
Eli Lilly Quarterly ROE - Return on Equity
Q2 2018 -2.24
Q1 2018 8.35
Q4 2017 -14.20
Q3 2017 3.71
Q2 2017 7.11
Q1 2017 -0.79
Q4 2016 5.48
Q3 2016 4.98
Q2 2016 5.10
Q1 2016 2.93
Q4 2015 3.28
Q3 2015 5.25
Q2 2015 4.09
Q1 2015 3.54
Q4 2014 2.79
Q3 2014 2.83
Q2 2014 4.08
Q1 2014 3.97
Q4 2013 4.12
Q3 2013 7.12
Q2 2013 7.92
Q1 2013 10.35
Q4 2012 5.60
Q3 2012 8.26
Q2 2012 6.46
Q1 2012 6.82
Q4 2011 6.34
Q3 2011 8.21
Q2 2011 8.39
Q1 2011 7.58
Q4 2010 9.42
Q3 2010 10.50
Q2 2010 13.18
Q1 2010 11.93
Q4 2009 9.61
Q3 2009 9.51
Q2 2009 13.53
Q1 2009 17.00
Q4 2008 -53.87
Q3 2008 -3.39
Q2 2008 6.51
Q1 2008 7.14
Q4 2007 6.33
Q3 2007 7.16
Q2 2007 5.74
Q1 2007 4.41
Q4 2006 1.21
Q3 2006 6.69
Q2 2006 6.89
Q1 2006 7.14
Q4 2005 6.70
Q3 2005 6.98
Q2 2005 -2.45
Q1 2005 6.35
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $113.359B $22.871B
Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $360.770B 17.24
Pfizer (PFE) United States $250.556B 14.67
Novartis AG (NVS) Switzerland $192.442B 16.51
Merck (MRK) United States $186.199B 16.44
AbbVie (ABBV) United States $149.625B 14.62
Novo Nordisk (NVO) Denmark $115.970B 18.54
Sanofi (SNY) France $105.440B 13.35
GlaxoSmithKline (GSK) United Kingdom $102.297B 13.66
Bristol-Myers Squibb (BMY) United States $99.527B 18.01
AstraZeneca (AZN) United Kingdom $96.554B 10.62